Amgen’s Phase 3 VESALIUS-CV data show Repatha cut death risk 20% in high-risk adults on statins—see ESC 2026 findings and key takeaways.

Sigma Planning Corp lessened its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 18.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,019 shares of the medical research company

Amgen has run roughly 51% in a year and now trades above the average Wall Street target, sitting near an all-time high after a Q2 beat-and-raise. The question buyers face is no longer whether the business works. It is whether anything is left at this price.

Amgen stock is holding above $430 as investors digest stronger-than-expected Q2 2026 results, double

Amgen stock is steady after second-quarter revenue of $10.05 billion and EPS of $6.29, with 2026 gui

Hennessy Advisors Inc. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 58.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 19,120 shares of the medical research company

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 12.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,390,910 shares of the medical

Van ECK Associates Corp lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 188,288 shares of the medical research company

Benjamin Edwards Inc. elevó su posición en Amgen Inc. (NASDAQ:AMGN - Free Report) un 10,0% en el segundo trimestre, según su presentación más reciente ante la Comisión de Bolsa y Valores. El inversor institucional poseía 74.607 acciones de la empresa de investigación médica

Wellington Management Group LLP boosted its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 1,102.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,742,271 shares of the medical research company

RB Capital Management LLC purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,121 shares of the medical research compa

Ferguson Wellman Capital Management Inc. lessened its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 22.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 247,072 shares of the medical research company

Caisse de depot et placement du Quebec trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 15.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,809 shares of the

Beacon Pointe Advisors LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 108,053 shares of the medical research company

Kingsview Wealth Management LLC acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 18,729 shares of the medical research company

Kimelman & Baird LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 14,240 shares of the medical research company

Nissay Asset Management Corp Japan boosted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 6.5% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 159,700 shares of the medical research company

Glenview Trust Co bought a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 8,321 shares of the medical research company